scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection
April 24, 2024 08:00 ET
|
scPharmaceuticals, Inc.
FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end...
scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
March 13, 2024 16:01 ET
|
scPharmaceuticals, Inc.
Generated 4Q 2023 net FUROSCIX® revenue of $6.1 million, at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023 Generated full-year...
scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024
March 06, 2024 16:01 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
February 28, 2024 16:01 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue
January 04, 2024 16:05 ET
|
scPharmaceuticals, Inc.
Company anticipates Q4 2023 net FUROSCIX revenue to be approximately $5.9 to $6.1 million; full-year net FUROSCIX revenue of approximately $13.4 to $13.6 million Gross-to-net (GTN) discount of...
scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
November 08, 2023 16:01 ET
|
scPharmaceuticals, Inc.
Generated net FUROSCIX® revenue of $3.8 million Ended Q3 2023 with cash, cash equivalents and short-term investments of $90.2 million Company to host investor conference call and webcast today,...
scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
November 01, 2023 16:05 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
October 31, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing...
scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives
September 19, 2023 08:00 ET
|
scPharmaceuticals, Inc.
Company advancing plans to expand the FUROSCIX franchise to include an 80mg/1ml auto-injector as an additional delivery system designed to provide greater flexibility to heart failure patients Agency...